Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | WEE1 | P30291 | 7/20 | 0.43 |
| ▸ | MYLK | Q15746 | 2/20 | 0.38 |
| ▸ | CNR2 | P34972 | 1/20 | 0.37 |
| ▸ | CHEK1 | O14757 | 4/20 | 0.36 |
| ▸ | SRC | P12931 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.34 |
| ▸ | HTR1A | P08908 | 1/20 | 0.34 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.34 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.34 |
| ▸ | DRD2 | P14416 | 1/20 | 0.34 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.34 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.34 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.34 |
| ▸ | DRD4 | P21917 | 1/20 | 0.34 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.34 |
| ▸ | HRH2 | P25021 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12608670 | 0.92 | WEE1 (0.41) | TP53WEE1MYLKCNR2CHEK1 | |
| SCHEMBL2361050 | 0.89 | TP53 (0.47) | TP53WEE1MYLKCNR2CHEK1 | |
| SCHEMBL15848959 | 0.89 | TP53 (0.49) | TP53WEE1MYLKCNR2CHEK1 | |
| SCHEMBL16131505 | 0.88 | TP53 (0.49) | TP53CNR2KDM4EALDH1A1HPGD | |
| SCHEMBL13419058 | 0.86 | WEE1 (0.42) | TP53WEE1MYLKCNR2CHEK1 | |
| SCHEMBL12608667 | 0.84 | WEE1 (0.40) | TP53WEE1MYLKCNR2CHEK1 | |
| SCHEMBL20828071 | 0.84 | WEE1 (0.38) | TP53WEE1MYLKCNR2CHEK1 | |
| SCHEMBL13637361 | 0.84 | TP53 (0.64) | TP53WEE1MYLKCNR2CHEK1 | |
| SCHEMBL2361620 | 0.82 | SMPD1 (0.40) | WEE1CNR2ALDH1A1KMT2AJAK2 | |
| SCHEMBL14472268 | 0.82 | MYLK (0.46) | TP53WEE1MYLKCNR2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2294186-B1 | INDUCING CELL DEATH BY INHIBITING ADAPTIVE HEAT SHOCK RESPONSE | INCURON INC (US) | 2019-10-09 | — | — | EP | disclosed |
| US-20190082845-A1 | CARBAZOLE COMPOUNDS AND THERAPEUTIC USES OF THE COMPOUNDS | INCURON INC (US) | 2019-03-21 | — | — | US | disclosed |
| US-20190082845-A1 | CARBAZOLE COMPOUNDS AND THERAPEUTIC USES OF THE COMPOUNDS | INCURON INC (US) | 2019-03-21 | — | — | US | disclosed |
| US-10137109-B2 | Carbazole compounds and therapeutic uses of the compounds | INCURON, INC. (US) | 2018-11-27 | — | — | US | disclosed |
| US-20170165229-A1 | CARBAZOLE COMPOUNDS AND THERAPEUTIC USES OF THE COMPOUNDS | INCURON, INC. | 2017-06-15 | — | — | US | disclosed |
| US-20170165229-A1 | CARBAZOLE COMPOUNDS AND THERAPEUTIC USES OF THE COMPOUNDS | INCURON, INC. | 2017-06-15 | — | — | US | disclosed |
| US-20170165229-A1 | CARBAZOLE COMPOUNDS AND THERAPEUTIC USES OF THE COMPOUNDS | INCURON, INC. | 2017-06-15 | — | — | US | disclosed |
| US-9566265-B2 | Carbazole compounds and therapeutic uses of the compounds | INCURON, LLC (US) | 2017-02-14 | — | — | US | disclosed |
| US-9566265-B2 | Carbazole compounds and therapeutic uses of the compounds | INCURON, LLC (US) | 2017-02-14 | — | — | US | disclosed |
| US-9566265-B2 | Carbazole compounds and therapeutic uses of the compounds | INCURON, LLC (US) | 2017-02-14 | — | — | US | disclosed |
| US-8765738-B2 | Carbazole compounds and therapeutic uses of the compounds | INCURON, LLC (US) | 2014-07-01 | — | — | US | disclosed |
| US-8765738-B2 | Carbazole compounds and therapeutic uses of the compounds | INCURON, LLC (US) | 2014-07-01 | — | — | US | disclosed |
| US-8765738-B2 | Carbazole compounds and therapeutic uses of the compounds | INCURON, LLC (US) | 2014-07-01 | — | — | US | disclosed |
| US-8486697-B2 | Inducing cell death by inhibiting adaptive heat shock response | INCURON, LLC (US) | 2013-07-16 | — | — | US | disclosed |
| EP-2356093-B1 | Carbazole compounds and therapeutic uses of the compounds | INCURON LLC (RU) | 2013-01-09 | — | — | EP | disclosed |
| EP-2356093-B1 | Carbazole compounds and therapeutic uses of the compounds | INCURON LLC (RU) | 2013-01-09 | — | — | EP | disclosed |
| US-20110305661-A1 | Carbazole Compounds and Therapeutic Uses of the Compounds | INCURON, INC. | 2011-12-15 | — | — | US | disclosed |
| US-20110305661-A1 | Carbazole Compounds and Therapeutic Uses of the Compounds | INCURON, INC. | 2011-12-15 | — | — | US | disclosed |
| US-20110305661-A1 | Carbazole Compounds and Therapeutic Uses of the Compounds | INCURON, INC. | 2011-12-15 | — | — | US | disclosed |
| WO-2009143290-A2 | INDUCING CELL DEATH BY INHIBITING ADAPTIVE HEAT SHOCK RESPONSE | CLEVELAND BIOLABS, INC (US) | 2009-11-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170165229-A1 | CARBAZOLE COMPOUNDS AND THERAPEUTIC USES OF THE COMPOUNDS | MALT1, PAICS, BCL9 | TP53 28/4885WEE1 1071/4885MYLK 3163/4885 |
| US-10137109-B2 | Carbazole compounds and therapeutic uses of the compounds | MALT1, PAICS, BCL9 | TP53 28/4885WEE1 1071/4885MYLK 3163/4885 |
| US-20110305661-A1 | Carbazole Compounds and Therapeutic Uses of the Compounds | MALT1, PAICS, TPMT | TP53 33/4885WEE1 1124/4885MYLK 3034/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.